Overview

Interleukin-11 Can Prevent and Treat of Radioactive Oral Mucitis

Status:
Recruiting
Trial end date:
2022-08-30
Target enrollment:
Participant gender:
Summary
Radiation induced oral mucositis which may result in reduced quality of life is commonly seen during radiotherapy, especially combined with chemotherapy. This study is a prospective, multicenter, and exploratory study. The aim of this study is to explore predictive factors of acute radiotherapy induced oral mucositis in nasopharyngeal carcinoma patients treated with radio-chemotherapy and reduce incidence of oral mucositis by using recombinant human interleukin -11.
Phase:
Phase 3
Details
Lead Sponsor:
Zhejiang Cancer Hospital
Treatments:
Oprelvekin